News | April 28, 2026
Essilor Stellest lens positioned as key breakthrough in myopia control in India
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The lens received U.S. Food and Drug Administration (FDA) market authorization via the De Novo pathway in late 2025
The approval was driven by data from the Phase III TULIP-SC trial
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Gilenya Capsules, 0.5 mg of Novartis Pharmaceuticals Corporation (Novartis)
The centre will leverage AI-enabled tools to support research and diagnostics for complex eye–brain disorders
Over the past decade, IIL has maintained a strong growth trajectory, registering a compound annual growth rate (CAGR) of 16%
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
India leads the shift as wellness tourism integrates healthcare, hospitality, and lifestyle
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
New appointments bring diagnostics and medtech expertise to strengthen healthcare delivery and policy engagement
Subscribe To Our Newsletter & Stay Updated
